)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
NextCure
NextCure (NXTC) investor relations material
NextCure Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Strategic focus shifted to completing the proposed Avere merger, supporting remaining agreements and monetizing legacy assets after sponsored clinical development wound down.
The S-4 became effective November 6, 2026; the stockholder vote was scheduled for December 9, subject to approval and customary closing conditions.
Restructuring and the LNCB74 transfer reduced future operating cash requirements.
Financial highlights
Q3 2026 net loss was $6.8M vs. $8.6M in Q3 2025; 9M net loss was $31.5M vs. $46.4M.
Q3 operating expenses were $6.9M vs. $8.9M; 9M operating expenses were $32.1M vs. $47.9M.
Q3 net loss improvement reflected lower R&D and $2.0M of net restructuring gains, partly offset by higher G&A.
Cash, cash equivalents and marketable securities were $8.7M at September 30, 2026, down from $41.8M at December 31, 2025.
Outlook and guidance
Existing cash was expected to fund operations into early 2027; future losses and uncertainty over merger completion raised substantial doubt about continuing as a going concern.
Research spending was expected to remain well below historical levels, with costs focused on transition support, contractual obligations, IP maintenance and legacy-asset monetization.
Approximately $820M in committed merger financing is intended to fund Avere’s AVR-001 development and future combined-company operations.
Subject to approval and customary conditions, the combined company was expected to operate as Avere and trade on Nasdaq as AVRX; existing stockholders were expected to retain a minority stake and receive contingent value rights tied to specified legacy assets.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NextCure
- SIM0505 demonstrates strong efficacy and safety in advanced ovarian and uterine cancers.NXTC
Corporate presentation - All-stock merger with Avere and $320M financing announced as net loss narrows to $14.9M.NXTCQ2 2026
- Once-weekly oral IL-23RA shows strong efficacy and safety, targeting multibillion-dollar markets.NXTCCorporate presentation
- All proposals were approved, with no stockholder questions or comments submitted.NXTCAGM 2026
- SIM0505 achieved 55% ORR and favorable safety in gynecologic cancers, supporting further trials.NXTCKOL event
- Two novel ADCs in Phase 1 trials show early promise for solid tumors, with 2026 milestones ahead.NXTCCorporate presentation
- Net loss narrowed to $9.8M in Q1 2026, but ongoing funding is needed for advancing ADC trials.NXTCQ1 2026
- Shareholders will vote on director elections, auditor ratification, executive pay, and incentive plan expansion.NXTCProxy filing
- Key votes include director elections, auditor ratification, and incentive plan amendment.NXTCProxy filing
Next NextCure earnings date
Q4 20265 Mar, 2027
NextCure
Next NextCure earnings date
Q4 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
NextCure Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomedicines to address cancer and other immune-related diseases by restoring normal immune function. The company's pipeline includes NC410, designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody targeting B7-H4, a protein found on various tumor types; and NC525, which targets LAIR-1 to eliminate AML blast cells and leukemic stem cells while sparing normal blood cells. NextCure's research also extends to preclinical evaluations of additional immunomodulatory molecules. NextCure is headquartered in Beltsville, Maryland, and its shares are listed on the Nasdaq.